Ignite Creation Date:
2024-05-06 @ 3:59 AM
Last Modification Date:
2024-10-26 @ 11:41 AM
Study NCT ID:
NCT02422290
Status:
COMPLETED
Last Update Posted:
2020-08-17
First Post:
2015-04-13
Brief Title:
Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder OCD
Sponsor:
New York State Psychiatric Institute
Organization:
New York State Psychiatric Institute
Study Overview
Official Title:
Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder OCD
Status:
COMPLETED
Status Verified Date:
2020-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This pilot study is proposed to determine the acceptability feasibility and potential efficacy of ketamine a medication that modulates glutamate in the brain as a rapid treatment for obsessive-compulsive disorder OCD symptoms in adolescents and young adults with OCD This study will recruit 6 youth ages 14-22 who are diagnosed with clinically significant OCD and have failed at least one adequate trial of a Serotonin Reuptake Inhibitor SRI medication and a course of Cognitive-Behavioral Therapy CBT unless unable to access or tolerate for OCD in the past Participants will receive a single infusion of intravenous ketamine and be assessed at regular intervals post-infusion for up to 14 days At the end of the 14-day treatment phase all participants will be offered three months of open treatment for OCD with medication andor CBT
Detailed Description:
See Brief Summary for description
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None